Compare WS & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WS | ANAB |
|---|---|---|
| Founded | 1955 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2023 | 2015 |
| Metric | WS | ANAB |
|---|---|---|
| Price | $31.80 | $64.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $47.00 | ★ $72.60 |
| AVG Volume (30 Days) | 210.4K | ★ 454.5K |
| Earning Date | 03-25-2026 | 03-03-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ 1.10 | N/A |
| Revenue | ★ $3,093,300,000.00 | $234,603,000.00 |
| Revenue This Year | $21.33 | N/A |
| Revenue Next Year | $3.41 | $43.04 |
| P/E Ratio | $28.78 | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $21.30 | $15.40 |
| 52 Week High | $49.17 | $68.39 |
| Indicator | WS | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 21.49 | 62.82 |
| Support Level | $29.63 | $43.67 |
| Resistance Level | $33.09 | N/A |
| Average True Range (ATR) | 1.47 | 3.94 |
| MACD | -0.89 | 0.58 |
| Stochastic Oscillator | 2.42 | 75.49 |
Worthington Steel Inc is a processor of carbon flat-rolled steel, a producer of laser-welded solutions, and a provider of electrical steel laminations. The company has manufacturing facilities across the United States, Canada, China, India, Germany and Mexico. It buys coils of steel from primary steel producers and processes them to precise type, thickness, length, width, shape, and surface quality required by customer specifications. The company's product lines and processing capabilities include; carbon flat-rolled steel processing, electrical steel laminations, and tailor welded products. Geographically, the company generates a majority of its revenue from the United States followed by Canada, Mexico, and other regions.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).